VantAI
Matthew McPartlon is a highly skilled professional in the field of machine learning and artificial intelligence, currently serving as Co-Founder at Chai Discovery since 2024. Previously, Matthew led the development of protein-protein interaction models at VantAI and served as tech lead for de novo antibody design modeling at Absci. An accomplished academic, Matthew earned a Ph.D. in Computer Science from the University of Chicago, where engagement as a Ph.D. student spanned from 2016 to 2023, including research scientist internships at Meta. Background education includes a Bachelor's degree in Mathematics and Computer Science with a minor in Economics from Hobart and William Smith Colleges.
This person is not in any offices
VantAI
1 followers
VantAI pairs bleeding-edge machine learning techniques with deep systems biology expertise to build computational models that uncover hidden relationships between molecules, targets, and diseases. These models power a best-in-class solution that identifies and generates new molecular entities for targets of interest, repurposes existing molecules at any stage of development, uncovers accurate ADME and toxicological insights, and predicts adverse events likely to influence trial success from deep analysis of systems-based pharmacogenomics. VantAI's in silico platform specializes in modelling complex protein-protein interactions, powering the discovery of biologics and protein degraders in addition to small-molecule drugs. It has helped leading biopharma partners launch new development programs--or revitalize old ones--at a fraction of the time and cost of traditional methods.